AI assistant
Sending…
TScan Therapeutics, Inc. — Director's Dealing 2021
Jul 16, 2021
34191_dirs_2021-07-15_acb11582-f3f4-49f5-8669-ab6d11dbacc1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-07-15
Reporting Person: Silver Brian M. (Chief Financial Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $5.82 | 2031-01-26 | Voting Common Stock (48780) | Direct |
Footnotes
F1: The shares subject to this option vest over 4 years of service following December 14, 2020, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
More from TScan Therapeutics, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 22
Interim / Quarterly Report
2026
May 6
Earnings Release
2026
May 6
Annual Report
2026
Apr 17
Proxy Solicitation & Information Statement
2026
Apr 17
Board/Management Information
2026
Apr 2
Annual Report
2026
Mar 4
Earnings Release
2026
Mar 4
Director's Dealing
2026
Jan 22
Director's Dealing
2026
Jan 22